Mutations, tissue accumulations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure

Environmental and Molecular Mutagenesis

Volumn 30, Issue 2, 1997, Pages 224-230

  Husgafvel Pursiainen, Kirsti ^a   Kannio, Annamaria ^a   Oksa, Panu ^a   Suitiala, Tuula ^a   Koskinen, Heikki ^a   Partanen, Riitta ^b   Hemminki, Kari ^b   Smith, Steven ^c   Rosenstock Leibu, Rachel ^c   Brandt Rauf, Paul W ^c  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Asbestos; Cancer; p53; Silica

Indexed keywords

ASBESTOS; PROTEIN P53; SILICON DIOXIDE;

ARTICLE; BIOACCUMULATION; BLOOD LEVEL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATION; OCCUPATIONAL CANCER;

ADULT; AGED; ASBESTOSIS; BASE SEQUENCE; ELECTROPHORESIS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; OCCUPATIONAL EXPOSURE; SILICOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030870088     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2280(1997)30:2<224::AID-EM15>3.0.CO;2-F     Document Type: Article

References (33)

1. Beck JS, Kwitek AE, Cogen PH, Metzger AK, Duyk GM, Sheffield VC (1993): A denaturing gradient gel electrophoresis assay for sensitive detection of p53 mutations. Hum Genet 91:25-30.
2. Brandt-Rauf PW, Smith S, Hemminki K, Koskinen H, Vainio H, Niman H, Ford J (1992): Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer 50:881-885.
3. Brandt-Rauf PW, Chen JM, Marion MJ, Smith SJ, Luo JC, Carney W, Pincus MR (1996): Conformational effects in the p53 protein of mutations induced during chemical carcinogenesis: Molecular dynamic and immunologic analyses. J Prot Chem 15:367-375.
4. Cote RJ, Jhanwar SC, Novick S, Pellicer A (1991): Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res 51:5410-5416.
5. Fontanini G, Fiore L, Bigini D, Vignati S, Calvo S, Mussi A, Lucchi M, Angeletti CA, Merlo GR, Basolo F (1994): Levels of p53 antigen in the serum of non-small cell lung cancer patients correlate with positive p53 immunohistochemistry on tumor sections, tumor necrosis and nodal involvement. Int J Oncol 5:553-558.
6. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994): Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
7. Greenblatt MS, Grollman AP, Harris CC (1996): Deletions and insertions in the p53 tumor suppressor gene in human cancers: Confirmation of the DNA polymerase slippage/misalignment model. Cancer Res 56:2130-2136.
8. Guinee DG, Travis WD, Trivers GE, De Benedetti VMG, Cawley H, Welsh JA, Bennett WP, Jett J, Colby TV, Tazelaar H, Abbondanzo SL, Pairolero P, Trastek V, Caporaso NE, Liotta LA, Harris CC (1995): Gender comparisons in human lung cancer: Analysis of p53 mutations, anti-p53 serum antibodies and c-erbB-2 expression. Carcinogenesis 16:993-1002.
9. Hall PA, Lane DP (1994): P53 in tumour pathology: Can we trust immunohistochemistry - Revisited. J Pathol 172:1-4.
10. Hei TK, Piao CQ, He ZY, Vannais D, Waldren CA (1992): Chrysotile fiber is a strong mutagen in mammalian cells. Cancer Res 52:6305-6309.
11. Hemminki K, Partanen R, Koskinen H, Smith S, Carney W, Brandt-Rauf PW (1996): The molecular epidemiology of oncoproteins: Serum p53 protein in patients with asbestosis. Chest 109:225-265.
12. Hesterberg TW, Barrett JC (1985): Induction by asbestos fibers of anaphase abnormalities: Mechanism for aneuploidy induction and possibly carcinogenesis. Carcinogenesis 6:473-475.
13. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC (1996): Somatic point mutation in the p53 gene of human tumors and cell lines: Updated compilation. Nucleic Acids Res 24:141-146.
14. Husgafvel-Pursiainen K, Ridanpaa M, Anttila S, Vainio H (1995): P53 and ras gene mutations in lung cancer: Implications for smoking and occupational exposures. J Occup Environ Med 37:69-76.
15. IARC (1996): 'Mechanisms of Fiber Carcinogenesis." Kane AB, Boffetta P, Saracci R, Wilbourn JD (eds): Lyon: International Agency for Research on Cancer Scientific Publications No. 140, 135 pp.
16. Jaurand MC, Bignon J (1994): "The Mesothelial Cell and Mesothelioma." New York: Marcel Dekker.
17. Kannio A, Ridanpaa M, Koskinen H, Partanen T, Anttila S, Collan Y, Hietanen E, Vainio H, Husgafvel-Pursiainen K (1996): A molecular and epidemiological study on bladder cancer: P53 mutations, tobacco smoking, and occupational exposure to asbestos. Cancer Epidemiol Biomarkers Prev 5:33-39.
18. Kelsey KT, Yano E, Liber HL, Little JB (1996): The in vitro genetic effects of fibrious erionite and crocidolite asbestos. Br J Cancer 54:107-114.
19. Kodama Y, Boreiko CJ, Maness SC, Hesterberg TW (1993): Cytotoxic and cytogenetic effects of asbestos on human bronchial epithelial cells in culture. Carcinogenesis 4:691-697.
20. Kondo K, Tsuzuki H, Sasa M, Sumitomo M, Uyama T, Monden Y (1996): A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol 61:20-26.
21. Lubin R, Zalcman G, Bouchet L, Tredaniel J, Legros Y, Cazals D, Hirsch A, Soussi T (1995): Serum p53 antibodies as early markers of lung cancer. Nature Med 1:701-702.
22. Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Gerwin BI, Harris CC (1992): P53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 52:2610-2615.
23. Nuorva K, Makitaro R, Huhti E, Kamel D, Vahakangas K, Bloigu R, Soini Y, Paakko P (1994): P53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. Am J Respir Crit Care Med 150:528-533.
24. Pincus MR, Brandt-Rauf PW, Nostro D (1996): Cell biology and early tumor detection. In Henry JB (ed): "Clinical Diagnosis and Management by Laboratory Methods." Philadelphia: WB Saunders Co., pp 310-321.
25. Ridanpaa M, Karjalainen A, Anttila S, Vainio H, Husgafvel-Pursiainen K (1994): Genetic alterations in p53 and K-ras in lung cancer in relation to histopathology of the tumor and smoking history of the patient. Int J Oncol 5:1109-1117.
26. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T (1994): Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69:809-816.
27. Smith-Sorensen B, Gebhardt MC, Kloen P, McIntyre J, Aguilar F, Cerutti P, Borresen A (1993): Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum Mutat 2:274-285.
28. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B (1994): Multifactorial analysis of p53 alteration in human cancer: A review. Int J Cancer 57:1-9.
29. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T, Ueda R (1992): P53 mutations in non-small-cell lung cancer in Japan - association between mutations and smoking. Cancer Res 52:734-736.
30. Takeshima Y, Seyama T, Bennett WP, Akiyama M, Tokuoka S, Inai K, Mabuchi K, Land CE, Harris CC (1993): P53 mutations in lung cancers from non-smoking atomic bomb survivors. Lancet 342:1520-1521.
31. 2 is directly related to increased proliferation and transformation of tracheal epithelial cells. Cancer Res 55:2723-2726.
32. Walker C, Everitt J, Barrett JC (1992): Possible cellular and molecular mechanisms for asbestos carcinogenicity. Am J Med 21:253-273.
33. Wang X, Christiani DC, Wiencke JK, Fischbein M, Xu X, Cheng TJ, Mark E, Wain JC, Kelsey KT (1995): Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol Biomarkers Prev 4:543-548.